Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Actio Biosciences

Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases
From Actio Biosciences
Via Business Wire
Actio Biosciences to Participate in Piper Sandler Spring Biopharma Symposium
From Actio Biosciences
Via Business Wire
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-0871, a Novel TRPV4 Inhibitor, for the Treatment of Charcot Marie Tooth Disease 2C
From Actio Biosciences
Via Business Wire
Actio Biosciences to Participate in Upcoming Investor Conferences
From Actio Biosciences
Via Business Wire
Actio Biosciences Expands Leadership Team with Appointment of Cayce Denton as Chief Financial Officer
From Actio Biosciences
Via Business Wire
Actio Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Actio Biosciences
Via Business Wire
Actio Biosciences to Participate in Upcoming Investor Conferences
From Actio Biosciences
Via Business Wire
Actio Biosciences to Participate in Upcoming October Investor Conferences
From Actio Biosciences
Via Business Wire
Actio Biosciences Appoints Dimitrios Arkilo, M.D., Experienced Neurologist and Epileptologist, as Chief Medical Officer
From Actio Biosciences
Via Business Wire
Actio Biosciences Receives Orphan Drug and Rare Pediatric Disease Designations for ABS-0871 for the Treatment of Charcot-Marie-Tooth Disease 2C
From Actio Biosciences
Via Business Wire
Renowned Rare-Disease Drug Developer Emil Kakkis, M.D., Ph.D., to Join Actio Biosciences Board of Directors
From Actio Biosciences
Via Business Wire
Actio Biosciences Appoints Ben Cravatt, Ph.D., to Board of Directors
From Actio Biosciences
Via Business Wire
Actio Biosciences Appoints Samuel Collins, MBBS, Ph.D., MBA, as Chief Medical Officer as Company Advances Multiple Precision Medicine Programs Toward Clinical Development
From Actio Biosciences
Via Business Wire
Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases
From Actio Biosciences
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.